Full text
PDFPage 977
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Caligiuri M. A., Murray C., Robertson M. J., Wang E., Cochran K., Cameron C., Schow P., Ross M. E., Klumpp T. R., Soiffer R. J. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest. 1993 Jan;91(1):123–132. doi: 10.1172/JCI116161. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cantrell D. A., Smith K. A. Transient expression of interleukin 2 receptors. Consequences for T cell growth. J Exp Med. 1983 Dec 1;158(6):1895–1911. doi: 10.1084/jem.158.6.1895. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gullberg M., Smith K. A. Regulation of T cell autocrine growth. T4+ cells become refractory to interleukin 2. J Exp Med. 1986 Feb 1;163(2):270–284. doi: 10.1084/jem.163.2.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Janssen R. A., Buter J., Straatsma E., Heijn A. A., Sleijfer D. T., de Vries E. G., Mulder N. H., The T. H., de Leij L. HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients. Cancer Immunol Immunother. 1993;36(3):198–204. doi: 10.1007/BF01741092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thompson J. A., Lee D. J., Lindgren C. G., Benz L. A., Collins C., Shuman W. P., Levitt D., Fefer A. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res. 1989 Jan 1;49(1):235–240. [PubMed] [Google Scholar]
- Vlasveld L. T., Hekman A., Vyth-Dreese F. A., Rankin E. M., Scharenberg J. G., Voordouw A. C., Sein J. J., Dellemijn T. A., Rodenhuis S., Melief C. J. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects. Br J Cancer. 1993 Sep;68(3):559–567. doi: 10.1038/bjc.1993.386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vlasveld L. T., Rankin E. M., Hekman A., Rodenhuis S., Beijnen J. H., Hilton A. M., Dubbelman A. C., Vyth-Dreese F. A., Melief C. J. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects. Br J Cancer. 1992 May;65(5):744–750. doi: 10.1038/bjc.1992.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yoshino I., Yano T., Murata M., Ishida T., Sugimachi K., Kimura G., Nomoto K. Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2. Cancer Res. 1991 Mar 1;51(5):1494–1498. [PubMed] [Google Scholar]